Genentech Announces Vemurafenib Improved Survival in People With Metastatic Melanoma Who Have BRAF V600 Mutations

Update: Zelboraf (vemurafenib) Now FDA Approved - August 17, 2011

-- Roche Group's Personalized Healthcare Approach Demonstrated Through Vemurafenib and its Investigational Companion Diagnostic, Roche's cobas 4800 BRAF V600 Mutation Test --

CHICAGO--(BUSINESS WIRE)--Jun 5, 2011 Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that a Phase III study (BRIM3) showed vemurafenib (RG7204, PLX4032) significantly improved overall survival (OS) in people with previously untreated BRAF V600 mutation-positive metastatic melanoma, compared to chemotherapy. In the study, the risk of death was reduced by 63 percent for people who received vemurafenib compared to those who received chemotherapy (hazard ratio [HR]=0.37, p<0.0001). In addition, vemurafenib significantly reduced the risk of the disease getting worse (progression-free survival, or PFS, a co-primary endpoint), by 74 percent compared to chemotherapy (HR=0.26, p<0.0001). The safety profile of vemurafenib was consistent with previous clinical studies.

“We are greatly encouraged by the results of BRIM3, which showed that vemurafenib not only extended life and reduced the risk of disease worsening, but also led to significant tumor shrinkage, an important result for this devastating cancer,” said Hal Barron, M.D., chief medical officer and head, Global Product Development. “We will continue to work closely with regulatory authorities to seek approval for vemurafenib and its companion diagnostic test to provide patients with BRAF-mutated metastatic melanoma a personalized option as soon as possible.”

Vemurafenib, a “BRAF-inhibitor,” is a personalized investigational medicine designed to specifically inhibit the activity of the mutant BRAF protein that is found in approximately half of all cases of melanoma, the deadliest and most aggressive form of skin cancer. People were enrolled into the study based on BRAF mutation status as determined by the cobas 4800 BRAF V600 Mutation Test, an investigational diagnostic from Roche.

“The joint development of the investigational cobas BRAF test and vemurafenib exemplifies how our personalized healthcare approach is one step closer to becoming a reality for patients,” said Paul Brown, head of Roche Molecular Systems. “In BRIM3 our investigational test enabled rapid and accurate identification of eligible patients with metastatic melanoma.”

The results are being featured in a press briefing titled, “Trials That Set New Standards of Care,” at 10:00 a.m. CDT on June 5th, 2011 at the Annual Meeting of the American Society of Clinical Oncology (ASCO), and will be presented by Paul Chapman, M.D., Memorial Sloan-Kettering Cancer Center in New York, principal investigator of the pivotal BRIM3 study, in the ASCO plenary session (Abstract #LBA4, June 5, 2011, 3:15 – 3:30 p.m. CDT, Hall B1). Data will also be published today in the online edition of the New England Journal of Medicine.

Additional data from the BRIM3 analysis showed:

 

  • The response rate (those who experienced tumor shrinkage) in the group of patients who received vemurafenib (48.4 percent) was nearly nine times higher than in the group who received chemotherapy (5.5 percent, p<0.0001).
  • After six months, 84 percent of patients who received vemurafenib were alive compared to 64 percent who received chemotherapy.
  • The improvement in OS, PFS and tumor shrinkage with vemurafenib was seen in patients regardless of age, gender or disease risk factor.
  • In January 2011, an independent data monitoring board reviewed data from a planned interim analysis of BRIM3 and recommended the release of study results due to compelling efficacy. The board also recommended that patients in the chemotherapy arm be permitted to cross over or receive vemurafenib instead of chemotherapy.
  • The median length of time patients lived (median OS) cannot be reliably estimated at this time because of the small number of patients in long-term follow-up. Median OS estimates when BRIM3 met this co-primary endpoint in January 2011 were 9.2 months in patients receiving vemurafenib and 7.8 months in those receiving chemotherapy; an additional two months of follow-up showed an estimated median OS of 10.5 months for patients receiving vemurafenib, while the median OS estimate for patients receiving chemotherapy remained at 7.8 months.
  • The safety profile of vemurafenib in BRIM3 was generally consistent with that previously reported in prior clinical studies. The most common Grade 3 or higher adverse events seen in more people receiving vemurafenib compared to those receiving chemotherapy were cutaneous squamous cell carcinoma (cSCC, a common type of skin cancer, 12 percent vs. <1 percent) and keratoacanthomas (6 percent vs. 0 percent), rash (8 percent vs. 0 percent), liver function abnormalities (7 percent vs. 1 percent), joint pain (3 percent vs. <1 percent) and sensitivity to the sun (3 percent vs. 0 percent). In cases of cSCC, the lesions were removed and the patients continued with treatment.

Vemurafenib has been granted priority review by the United States (U.S.) Food and Drug Administration. Roche/Genentech recently announced the submission of new drug applications for vemurafenib in the U.S. and European Union (EU). While the companies seek regulatory approval of vemurafenib, a global Expanded Access Program (EAP) is available for people with previously treated or untreated BRAF V600 mutation-positive metastatic melanoma.

About BRIM3

BRIM3 (Study NO25026) is a global, randomized, open-label, controlled, multicenter, Phase III study that compared vemurafenib to dacarbazine chemotherapy, a current standard of care, in 675 patients with previously untreated BRAF V600 mutation-positive, unresected, locally advanced or metastatic melanoma. Co-primary endpoints were OS and PFS. Secondary endpoints included response rate, response duration and safety profile.

Other Vemurafenib Data at ASCO

Updated results from a single-arm Phase II study (BRIM2) of vemurafenib in previously treated BRAF V600 mutation-positive metastatic melanoma were also presented in an oral session by Antoni Ribas, M.D., UCLA Jonsson Comprehensive Cancer Center (Abstract #8509). Additionally, results are being presented from an analysis of patients enrolled in a single-arm study that is exploring the use of vemurafenib in tumors that have spread to the brain (brain metastases) in people with BRAF V600 mutation-positive metastatic melanoma (Abstract #8548).

About BRIM2

BRIM2 (Study NP22657) is a global, single-arm, multicenter, open-label Phase II study that enrolled 132 patients with previously treated BRAF V600 mutation-positive metastatic melanoma. Unlike BRIM3, BRIM2 enrolled people who had previously received a treatment for metastatic melanoma. The primary endpoint of the study was best overall response rate and the updated data showed that 53 percent of patients had tumor shrinkage (median duration of response=6.7 months). People who participated in BRIM2 also lived a median of 6.7 months without their disease getting worse (median PFS). Median OS has not yet been reached after a median follow-up of 10 months.

The safety profile of vemurafenib in BRIM2 was generally consistent with that previously reported in clinical studies of vemurafenib. Grade 3 cSCC was reported in 26 percent of patients. In cases of cSCC, the lesions were removed and the patients continued with treatment. The most common adverse events of any severity were joint pain (59 percent), rash (52 percent), sensitivity to the sun (52 percent) and fatigue (42 percent).

About the Vemurafenib Brain Metastases Safety Study

The vemurafenib brain metastases safety study is a single-arm, open-label study enrolling 20 patients with BRAF V600 mutation-positive metastatic melanoma with brain metastases. Preliminary data from patients enrolled in the study to date suggested that vemurafenib may have activity in brain metastases. The safety profile of vemurafenib was generally consistent with that observed in other clinical trials.

Roche/Genentech is planning to initiate a global, multicenter Phase II study exploring the efficacy and safety profile of vemurafenib in people with BRAF V600 mutation-positive metastatic melanoma that has spread to the brain.

About Metastatic Melanoma and BRAF

When melanoma is caught early, it is generally a curable disease. However, when it spreads to other parts of the body, it is the deadliest and most aggressive form of skin cancer. A person with metastatic melanoma typically has on average a short life expectancy that is measured in months. The American Cancer Society estimates there were almost 70,000 new cases of melanoma and more than 8,000 melanoma deaths last year in the U.S. alone.

The BRAF protein is a key component of the RAS-RAF pathway involved in normal cell growth and survival. Mutations that lock the BRAF protein in an active state may cause excessive signaling in the pathway, leading to uncontrolled cell growth and survival. These mutations are thought to occur in an estimated half of all cases of melanoma and eight percent of solid tumors.

About Vemurafenib

Vemurafenib is an investigational, oral, small molecule that is designed to selectively inhibit a cancer-driving mutated form of the BRAF protein. Vemurafenib is being co-developed under a 2006 license and collaboration agreement between Roche/Genentech and Plexxikon, a member of the Daiichi Sankyo Group.

Genentech is pursuing a broad development program with vemurafenib that includes combinations with other medicines (both approved and investigational, from Genentech and other companies), as well as studies in other tumor types. While Roche/Genentech seek approval of vemurafenib, vemurafenib is available to eligible patients with BRAF V600 mutation-positive metastatic melanoma through a global patient access program. More information about this program or other vemurafenib studies is available at http://www.clinicaltrials.gov (in the U.S.) or the Roche Clinical Trials Registry at http://www.roche-trials.com (in the EU). Genentech can also be contacted by calling the company's clinical trial call center at 888-662-6728 or by emailing genentechclinicaltrials@druginfo.com.

About the cobas 4800 BRAF V600 Mutation Test

The cobas 4800 BRAF V600 Mutation Test is an investigational, polymerase chain reaction-based companion diagnostic being developed by Roche to identify people whose tumors carry the BRAF V600 mutation. Roche submitted a Premarket Approval Application (PMA) for the cobas 4800 BRAF V600 Mutation Test in the U.S. The test will also be registered in Europe.

Important Safety Information for Vemurafenib

The most frequent Grade 3 adverse event observed in clinical trials of vemurafenib was cSCC, a common skin cancer treated by local excision (minor surgery done in a physician's office). The most common adverse events were rash, increased sun sensitivity, joint pain, hair loss and fatigue. Possible serious side effects of vemurafenib include liver problems, changes in heartbeat or very fast or abnormal heartbeats and allergic reactions.

About Genentech

Founded more than 30 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.

Contact: Genentech
Media Contact:
Krysta Pellegrino, 650-467-6800
or
Advocacy Contact:
Sonali Padhi, 650-467-0842
or
Investor Contacts:
Thomas Kudsk Larsen, 650-467-2016
Karl Mahler, 011 41 61 687 8503

 

Posted: June 2011

View comments

Hide
(web1)